Nasdaq
$29.25▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.30BShares out 78.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 10.7Regular26.10.08 00:47SCHEDULE 13G/AOwnership#●●●#●●●
Celldex Therapeutics, Inc.
FMR LLC and its affiliates have filed a Schedule 13G/A reporting their beneficial ownership of Celldex Therapeutics, Inc. common stock as of September 30, 2026. This filing represents a joint report by FMR LLC and its related entities, including Abigail P. Johnson.…more
$29.25+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22Pre-market26.09.22 20:098-KKey event
Celldex Therapeutics, Inc.
Celldex Therapeutics announced positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab, which met all primary and key secondary endpoints in patients with chronic spontaneous urticaria. Based on these results, the company plans to submit a Biologics License Application (BLA) to the FDA in 2027.…more
$29.25+0.00%vs prev closeView filingShare - 8.6After-hours26.08.07 05:0610-QEarnings
Celldex Therapeutics, Inc.
셀덱스 테라퓨틱스는 2026년 2분기 매출 2만 2천 달러, 순손실 7,350만 달러(주당 순손실 0.94달러)를 기록했습니다. 2026년 상반기 누적 순손실은 1억 5,218만 달러로, 연구개발비 증가에 따라 전년 동기 대비 손실 규모가 확대되었습니다.…more
$29.25+0.00%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.22Regular26.09.23 01:25#●●●#●●●
Celldex Reports Positive Phase 3 Results for CSU Treatment, Plans 2027 FDA Filing…more
Celldex Therapeutics successfully met all primary and secondary endpoints in its Phase 3 trials for barzolvolimab in treating chronic spontaneous urticaria. While the company plans to submit a BLA to the FDA in 2027, the stock price declined following the announcement.…more
$29.25+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.22Pre-market26.09.22 20:05
●●●●●●●● ●●●●● ●●●●●●
Celldex announced that its Phase 3 trials for barzolvolimab successfully met all primary and key secondary endpoints in patients with chronic spontaneous urticaria. The company demonstrated sustained efficacy and a favorable safety profile, with plans to submit a BLA in 2027.…more
$29.25+0.00%vs prev closeShareBenzinga - 9.22Pre-market26.09.22 19:58
●●●●●●●● ●●●●● ●●●●●●
Celldex announced that its Phase 3 trials for barzolvolimab in chronic spontaneous urticaria met all primary and key secondary endpoints. The company plans to submit a Biologics License Application to the FDA in 2027 based on these positive results.…more
$29.25+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report